Our results suggest that the origin of infection partly explains sepsis heterogeneity and should be considered when selecting patients for clinical trials testing the role of immunomodulatory agents such as steroids, monoclonal antibodies, interferon-gamma, and granulocyte-macrophage colony-stimulating factor in the outcomes of sepsis [10]. Here, CSF2 is linked to infection.